Question 1

What is Cordex Biologics?

Accepted Answer

Cordex Biologics is a Entity.

Question 2

How often does Cordex Biologics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Cordex Biologics first tracked by Ergen?

Accepted Answer

First tracked on Jun 10, 2026.

Question 4

When was Cordex Biologics last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is Cordex Biologics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Cordex Biologics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Cordex Biologics?

Accepted Answer

Medexus licenses Zemcelpro for Canada (Jun 10, 2026, 6 articles).

Question 8

How did the "Medexus licenses Zemcelpro for Canada" event impact Cordex Biologics?

Accepted Answer

Cordex Biologics, a wholly owned subsidiary of ExCellThera, has granted exclusive licensing and supply agreements to Medexus Pharmaceuticals for the Canadian commercialization rights of Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel, which includes royalties and milestone payments.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.